Mineralys Therapeutics, Inc. (MLYS) Tuesday reported positive topline data from its Phase 2 Explore-CKD study of lorundrostat for the treatment of hypertension in people with chronic kidney disease (CKD) and albuminuria. The study met its primary goal.
The Explore-CKD crossover study was designed to evaluate efficacy in terms of systolic blood pressure (BP) and urine albumin-to-creatinine ratio (UACR) reduction and safety of lorundrostat in CKD subjects. Patients treated with lorundrostat showed statistically significant 30.51% reduction in UACR ratio. Further, a reduction of 9.25 mmHg in systolic blood pressure was observed.
Lorundrostat also demonstrated a favorable safety and tolerability profile.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.